Abstract
Essential thrombocythemia (ET) is a rare disorder in children. An 11-year-old white boy was first seen in January 1986 with symptoms of abdominal pain. His platelet count was 1.5 million/mm3. Other hematological values and coagulation studies, including bleeding time, were normal. There was laboratory evidence of mild platelet dysfunction. Using the criteria of the Polycythemia Vera Study Group, a diagnosis of ET was made. He developed frequent headaches. Aspirin was prescribed for the next 2 years at varying doses and frequency. During this period, platelet counts ranged between 1 and 3 million/mm3. In view of progressive headaches and evidence of increasing platelet dysfunction, further treatment was indicated. The use of a new agent, anagrelide, reported effective in adults with ET, resulted in amelioration of symptoms and improvement in quantitative and qualitative platelet control with no significant untoward effects.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 52-56 |
| Number of pages | 5 |
| Journal | Journal of pediatric hematology/oncology |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 1991 |
Keywords
- Anagrelide
- Essential thrombocythemia
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology
Fingerprint
Dive into the research topics of 'Essential thrombocythemia in a child: Management with anagrelide'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS